The landscape of therapeutic interventions for diabetes mellitus type 2 and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, compounds like Reta, demonstrating impressive https://keiranukqp923101.loginblogin.com/46929365/glp-3-receptor-agonists-reta-trizepatide-and-beyond